Skip to main
MTNB
MTNB logo

MTNB P/E Ratio

P/E Ratio as of Jun 13, 2025: -0.21

Average-0.2095
Median-0.2100
Minimum-0.2600
Maximum-0.1900
-0.21
Past Month-0.04 (23.53%)
The P/E ratio for MTNB is -0.21 as of Jun 13, 2025. This represents a decrease of -55.32% compared to its 12-month average P/E ratio of -0.47. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.

Matinas BioPharma Hlds P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)

Matinas BioPharma Hlds’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Matinas BioPharma Hlds to industry peers.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

MTNB P/E Ratio Historic Data

DateStock priceP/E ratio
Jun 2, 2025$0.82-0.21
May 1, 2025$0.62-0.12
Apr 1, 2025$0.57-0.13
Mar 3, 2025$0.55-0.12
Feb 3, 2025$0.574-0.13
Jan 2, 2025$0.588-0.13

MTNB End of Year P/E Ratio

DateP/E ratioChange
2025-0.21+90.91%
2024-0.11-95.02%
2023-2.21-50.89%
2022-4.50-49.94%
2021-8.99-22.03%
2020-11.53

FAQs About Matinas BioPharma Hlds (MTNB) P/E ratio

The latest P/E ratio of MTNB is -0.21, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).

Matinas BioPharma Hlds’s last 12-month average P/E ratio is -0.47, compared to its current P/E ratio of -0.21. This reflects a decrease of -55.32%.

Matinas BioPharma Hlds’s current P/E ratio of -0.21 is lower than its last 12-month average P/E of -0.47. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.

Matinas BioPharma Hlds’s average P/E ratio over the last 3 years is -2.92. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.

Matinas BioPharma Hlds’s average P/E ratio over the last 5 years is -4.93. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.

Matinas BioPharma Hlds (MTNB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.